Cipher Pharmaceuticals Stock Price, News & Analysis (TSE:CPH)

C$4.35 0.13 (3.08 %)
(As of 01/16/2018 12:20 PM ET)
Previous CloseC$4.22
Today's RangeC$4.20 - C$4.35
52-Week RangeC$4.20 - C$5.75
Volume5,750 shs
Average Volume15,846 shs
Market CapitalizationC$112.64 million
P/E Ratio-19.77
Dividend YieldN/A
Beta1.54

About Cipher Pharmaceuticals (TSE:CPH)

Cipher Pharmaceuticals logoCipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. The company also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Sitavig, a tablet for the treatment of herpes labialis in immunocompetent adults. In addition, it offers NUVAIL, a polymer solution for managing the signs and symptoms of nail dystrophy; and BIONECT, a topical hyaluronic acid for the treatment of signs and symptoms of skin irritation. The company’s pipeline products include Ozenoxacin that has completed Phase III clinical trials to treat adult and paediatric patients with impetigo; Dermadexin, a topical barrier-repair cream for treating seborrheic dermatitis; Pruridexin, a topical cream for the treatment of chronic pruritis; and CF101, an oral small molecule drug that is used for the treatment of plaque psoriasis and rheumatoid arthritis. It also develops pre-clinical compounds for the treatment of melanoma and other cancers; and tattoo removal creams, which is in the pre-clinical stage. The Cipher Pharmaceuticals Inc. has a licensing agreement with Edesa Biotech Inc. for developing, marketing, and sale of ASF-1096 for the treatment of anorectal indications. The company was founded in 2004 and is headquartered in Mississauga, Canada.

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:CPH
CUSIPN/A
Phone+1-905-6025840

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-19.7727272727273
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.22)
Net IncomeN/A
Net Margins44.75%
Return on Equity113.74%
Return on Assets26.78%

Miscellaneous

EmployeesN/A
Outstanding Shares26,689,000

Cipher Pharmaceuticals (TSE:CPH) Frequently Asked Questions

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (TSE:CPH) posted its quarterly earnings results on Friday, November, 3rd. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.18 by $0.04. Cipher Pharmaceuticals had a net margin of 44.75% and a return on equity of 113.74%. View Cipher Pharmaceuticals' Earnings History.

When will Cipher Pharmaceuticals make its next earnings announcement?

Cipher Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Cipher Pharmaceuticals.

Where is Cipher Pharmaceuticals' stock going? Where will Cipher Pharmaceuticals' stock price be in 2018?

2 brokerages have issued 12 month price targets for Cipher Pharmaceuticals' stock. Their forecasts range from C$5.00 to C$8.00. On average, they anticipate Cipher Pharmaceuticals' stock price to reach C$6.50 in the next twelve months. View Analyst Ratings for Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:

  • John D. Mull M.D., Chairman of the Board (Age 83)
  • Robert D. Tessarolo, President, Chief Executive Officer
  • Stephen L. Lemieux CPA, Chief Financial Officer, Secretary
  • Ralph Bohrer, President and General Manager of US Business (Age 54)
  • Joan Chypyha, President, General Manager - Canada
  • Joseph Pecora, President and General Manager - USA
  • Lorne Markowitz, Vice President of Sales and Marketing
  • Linda Melanie Angaritis, Vice President - Global Regulatory Compliance and Quality
  • Louise Blythe, Vice President - Regulatory Affairs
  • Lynne Cheryl Bulger, Vice President - Medical and Clinical Affairs

How do I buy Cipher Pharmaceuticals stock?

Shares of Cipher Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of Cipher Pharmaceuticals stock can currently be purchased for approximately C$4.35.

How big of a company is Cipher Pharmaceuticals?

Cipher Pharmaceuticals has a market capitalization of C$112.64 million.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.


MarketBeat Community Rating for Cipher Pharmaceuticals (CPH)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cipher Pharmaceuticals (TSE:CPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.33
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$6.50C$6.50C$7.25C$6.75
Price Target Upside: 44.44% upside44.44% upside38.36% upside29.31% upside

Cipher Pharmaceuticals (TSE:CPH) Consensus Price Target History

Price Target History for Cipher Pharmaceuticals (TSE:CPH)

Cipher Pharmaceuticals (TSE:CPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/7/2017TD SecuritiesLower Price TargetHoldC$6.50 -> C$5.00View Rating Details
8/14/2017Bloom BurtonDowngradeBuy -> HoldView Rating Details
5/12/2017CIBCBoost Price TargetC$7.50 -> C$8.00View Rating Details
8/11/2016GMP SecuritiesDowngradeBuy -> HoldView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Cipher Pharmaceuticals (TSE:CPH) Earnings History and Estimates Chart

Earnings by Quarter for Cipher Pharmaceuticals (TSE:CPH)

Cipher Pharmaceuticals (TSE CPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018        
11/3/2017Q3 2017C$0.18C$0.22ViewN/AView Earnings Details
8/11/2017Q2 2017C$0.22C$0.23ViewN/AView Earnings Details
5/11/2017Q1 2017C$0.02C$0.09ViewN/AView Earnings Details
3/2/2017Q4 2016C($0.07)C($0.08)ViewN/AView Earnings Details
11/11/2016Q3 2016C($0.11)C($0.11)ViewN/AView Earnings Details
8/3/2016Q2 2016C($0.03)C($0.08)ViewN/AView Earnings Details
5/5/2016Q1 2016C($0.04)C($0.14)ViewN/AView Earnings Details
2/24/2016Q4 2015C($0.02)C$0.10ViewN/AView Earnings Details
11/4/2015Q3 2015C($0.04)ViewN/AView Earnings Details
8/14/2015Q2 2015C$0.02ViewN/AView Earnings Details
5/13/2015Q1 2015C$0.17C$0.12ViewN/AView Earnings Details
2/25/2015Q4 2014C$0.15C$0.14ViewN/AView Earnings Details
10/29/2014Q3 2014C$0.14C$0.17ViewN/AView Earnings Details
7/31/2014C$0.18C$0.17ViewN/AView Earnings Details
5/5/2014C$0.19C$0.15ViewN/AView Earnings Details
2/26/2014Q4 2013C$0.26C$0.17ViewN/AView Earnings Details
10/30/2013Q3 2013C$0.14C$0.13ViewN/AView Earnings Details
7/31/2013Q2 2013C$0.06C$0.12ViewN/AView Earnings Details
5/3/2013Q1 2013C$0.04C$0.06ViewN/AView Earnings Details
3/1/2013Q4 2012C$0.04C$0.06ViewN/AView Earnings Details
10/24/2012Q3 2012C$0.04C$0.03ViewN/AView Earnings Details
7/25/2012Q2 2012C($0.01)C$0.01ViewN/AView Earnings Details
5/4/2012Q1 2012C$0.01ViewN/AView Earnings Details
2/22/2012Q4 2011C($0.01)C($0.02)ViewN/AView Earnings Details
10/26/2011Q3 2011C($0.01)ViewN/AView Earnings Details
7/26/2011Q2 2011C($0.02)ViewN/AView Earnings Details
5/12/2011Q1 2011C($0.05)ViewN/AView Earnings Details
10/27/2010Q3 2010C($0.01)ViewN/AView Earnings Details
7/28/2010Q2 2010C$0.03ViewN/AView Earnings Details
4/23/2010Q1 2010C($0.02)ViewN/AView Earnings Details
2/17/2010Q4 2009C($0.03)ViewN/AView Earnings Details
11/4/2009Q3 2009C($0.02)ViewN/AView Earnings Details
7/29/2009Q2 2009C($0.03)ViewN/AView Earnings Details
5/13/2009Q1 2009C($0.03)ViewN/AView Earnings Details
2/18/2009Q4 2008C($0.02)ViewN/AView Earnings Details
11/7/2008Q3 2008C$0.01ViewN/AView Earnings Details
8/13/2008Q2 2008C($0.08)ViewN/AView Earnings Details
5/1/2008Q1 2008C($0.04)ViewN/AView Earnings Details
2/27/2008Q4 2007C($0.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Cipher Pharmaceuticals (TSE:CPH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Cipher Pharmaceuticals (TSE:CPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cipher Pharmaceuticals (TSE CPH) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Cipher Pharmaceuticals (TSE:CPH)

Cipher Pharmaceuticals (TSE CPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2017Harold Morton WolkinDirectorBuy35,000C$4.69C$164,150.00
6/30/2017John MullInsiderBuy1,900C$5.70C$10,830.00
6/28/2017John MullInsiderBuy8,500C$5.57C$47,345.00
6/16/2017John MullInsiderBuy3,400C$5.55C$18,870.00
6/15/2017John MullInsiderBuy6,500C$5.55C$36,075.00
6/14/2017John MullInsiderBuy3,700C$5.55C$20,535.00
6/13/2017John MullInsiderBuy5,000C$5.55C$27,750.00
6/12/2017John MullInsiderBuy5,000C$5.55C$27,750.00
6/9/2017John MullInsiderBuy5,000C$5.50C$27,500.00
6/6/2017Mark BeaudetDirectorBuy1,400C$5.65C$7,910.00
6/5/2017Mark BeaudetDirectorBuy18,600C$5.65C$105,090.00
5/30/2017Harold Morton WolkinDirectorBuy15,000C$5.57C$83,550.00
5/17/2017Harold Morton WolkinDirectorBuy23,700C$5.45C$129,165.00
5/16/2017Harold Morton WolkinDirectorBuy10,500C$5.35C$56,175.00
(Data available from 1/1/2013 forward)

Headlines

Cipher Pharmaceuticals (TSE CPH) News Headlines

Source:
DateHeadline
Cipher Pharmaceuticals and Italmex Pharma Announce Exclusive Distribution Agreement for Isotretinoin Product in MexicoCipher Pharmaceuticals and Italmex Pharma Announce Exclusive Distribution Agreement for Isotretinoin Product in Mexico
finance.yahoo.com - January 9 at 9:10 AM
Cipher Pharmaceuticals Announces Canadian Launch of OZANEX™ (ozenoxacin cream 1%), a Novel Topical AntibioticCipher Pharmaceuticals Announces Canadian Launch of OZANEX™ (ozenoxacin cream 1%), a Novel Topical Antibiotic
finance.yahoo.com - January 8 at 8:16 AM
Cipher Pharmaceuticals Inc (CPH) Director Harold Morton Wolkin Buys 35,000 SharesCipher Pharmaceuticals Inc (CPH) Director Harold Morton Wolkin Buys 35,000 Shares
www.americanbankingnews.com - November 12 at 12:14 PM
Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
finance.yahoo.com - November 10 at 5:19 PM
Cipher Pharmaceuticals Inc (CPH) to Post FY2017 Earnings of $0.49 Per Share, Cormark ForecastsCipher Pharmaceuticals Inc (CPH) to Post FY2017 Earnings of $0.49 Per Share, Cormark Forecasts
www.americanbankingnews.com - November 7 at 5:54 AM
Cipher Pharmaceuticals Reports Q3 2017 Operating & Financial ResultsCipher Pharmaceuticals Reports Q3 2017 Operating & Financial Results
finance.yahoo.com - November 4 at 7:11 AM
Cipher Pharmaceuticals Announces New Credit FacilityCipher Pharmaceuticals Announces New Credit Facility
finance.yahoo.com - November 4 at 7:11 AM
Edited Transcript of CPH.TO earnings conference call or presentation 3-Nov-17 12:30pm GMTEdited Transcript of CPH.TO earnings conference call or presentation 3-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 7:11 AM
Cipher Pharmaceuticals Inc (CPH) to Release Quarterly Earnings on FridayCipher Pharmaceuticals Inc (CPH) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - October 27 at 1:34 AM
/C O R R E C T I O N from Source -- Cipher Pharmaceuticals Inc.//C O R R E C T I O N from Source -- Cipher Pharmaceuticals Inc./
finance.yahoo.com - October 17 at 6:13 PM
Cipher Pharmaceuticals Comments on Supply Chain Impact from Hurricane MariaCipher Pharmaceuticals Comments on Supply Chain Impact from Hurricane Maria
finance.yahoo.com - October 10 at 6:37 PM
Cipher Pharmaceuticals Comments on FDA Warning Letter for ConZip® (Tramadol)Cipher Pharmaceuticals Comments on FDA Warning Letter for ConZip® (Tramadol)
finance.yahoo.com - September 7 at 5:35 PM
Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 22, 2017
finance.yahoo.com - August 22 at 5:59 PM
Todays Research Reports on Cipher Pharmaceuticals Inc., Canopy Growth Corporation, Titan Medical Inc. and Nuvo Pharmaceuticals Inc.Today's Research Reports on Cipher Pharmaceuticals Inc., Canopy Growth Corporation, Titan Medical Inc. and Nuvo Pharmaceuticals Inc.
finance.yahoo.com - August 16 at 5:53 PM
Cipher Pharmaceuticals Inc to Post FY2017 Earnings of $0.47 Per Share, Cormark Forecasts (CPH)Cipher Pharmaceuticals Inc to Post FY2017 Earnings of $0.47 Per Share, Cormark Forecasts (CPH)
www.americanbankingnews.com - August 16 at 7:54 AM
Cipher Pharmaceuticals Inc Forecasted to Post Q3 2017 Earnings of $0.17 Per Share (CPH)Cipher Pharmaceuticals Inc Forecasted to Post Q3 2017 Earnings of $0.17 Per Share (CPH)
www.americanbankingnews.com - August 15 at 8:14 AM
Cipher Pharmaceuticals Inc (CPH) Rating Lowered to Hold at Bloom BurtonCipher Pharmaceuticals Inc (CPH) Rating Lowered to Hold at Bloom Burton
www.americanbankingnews.com - August 15 at 7:40 AM
Cipher Pharmaceuticals Inc (TSE:CPH) PT Raised to C$6.50Cipher Pharmaceuticals Inc (TSE:CPH) PT Raised to C$6.50
www.americanbankingnews.com - August 14 at 7:20 PM
Edited Transcript of CPH.TO earnings conference call or presentation 11-Aug-17 12:30pm GMTEdited Transcript of CPH.TO earnings conference call or presentation 11-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 10:54 PM
Cipher Pharmaceuticals reports Q2 2017 financial resultsCipher Pharmaceuticals reports Q2 2017 financial results
finance.yahoo.com - August 11 at 5:53 PM
Cipher Pharmaceuticals Inc (CPH) Scheduled to Post Quarterly Earnings on FridayCipher Pharmaceuticals Inc (CPH) Scheduled to Post Quarterly Earnings on Friday
www.americanbankingnews.com - August 4 at 7:12 AM
Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Cipher Pharmaceuticals Ltd. :CPH-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
finance.yahoo.com - August 3 at 10:17 PM
Cipher Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : CPH-CA : August 2, 2017Cipher Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : CPH-CA : August 2, 2017
finance.yahoo.com - August 2 at 6:13 PM
Notice of Cipher Pharmaceuticals Q2 2017 Conference CallNotice of Cipher Pharmaceuticals Q2 2017 Conference Call
finance.yahoo.com - July 25 at 5:25 PM
Notice of Cipher Pharmaceuticals Q2 2017 Conference CallNotice of Cipher Pharmaceuticals Q2 2017 Conference Call
finance.yahoo.com - July 25 at 5:25 PM
Cipher Pharmaceuticals Enters Oversold Territory (CPH)Cipher Pharmaceuticals Enters Oversold Territory (CPH)
www.thestreet.com - July 17 at 5:48 PM
Cipher Pharmaceuticals Ltd. – Value Analysis (TORONTO:CPH) : July 12, 2017Cipher Pharmaceuticals Ltd. – Value Analysis (TORONTO:CPH) : July 12, 2017
finance.yahoo.com - July 12 at 6:10 PM
Cipher Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : CPH-CA : July 11, 2017Cipher Pharmaceuticals Ltd. breached its 50 day moving average in a Bullish Manner : CPH-CA : July 11, 2017
finance.yahoo.com - July 11 at 6:34 PM
Cipher Pharmaceuticals Inc (CPH) Insider Purchases C$10,830.00 in StockCipher Pharmaceuticals Inc (CPH) Insider Purchases C$10,830.00 in Stock
www.americanbankingnews.com - July 4 at 2:12 PM
Q4 2016 Cipher Pharmaceuticals Inc Earnings Release - Before Market OpenQ4 2016 Cipher Pharmaceuticals Inc Earnings Release - Before Market Open
biz.yahoo.com - March 2 at 7:30 AM
Arrowhead Blunted, CERC Depressed, Its All Clear For NOVN, CPHR Leaves Nasdaq - NasdaqArrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq - Nasdaq
www.nasdaq.com - November 30 at 9:26 AM
Exclusive: Canada drugmaker Cipher mulls sale - sourcesExclusive: Canada drugmaker Cipher mulls sale - sources
www.reuters.com - October 31 at 4:27 PM
Q1 2016 Cipher Pharmaceuticals Inc Earnings Release - Time Not SuppliedQ1 2016 Cipher Pharmaceuticals Inc Earnings Release - Time Not Supplied
biz.yahoo.com - May 5 at 7:07 AM
Q4 2015 Cipher Pharmaceuticals Inc Earnings Release - Time Not SuppliedQ4 2015 Cipher Pharmaceuticals Inc Earnings Release - Time Not Supplied
biz.yahoo.com - February 24 at 7:07 AM

SEC Filings

Cipher Pharmaceuticals (TSE:CPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Cipher Pharmaceuticals (TSE CPH) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.